Clinical trialNCT04363164RecruitingPhase 2Interventional

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

SponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrollment150Castration Resistant Metastatic Prostate Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Samuel Denmeade, MD
SKCCC at Johns Hopkins
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California, San Diego (ucsd)
San Diego, California, United States
Rana McKay, MD
Recruiting
Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Samuel R. Denmeade
Recruiting
Dana-Faber Cancer Institute
Boston, Massachusetts, United States
Jacob Berchuck, MD
Recruiting
University of Minnesota
Minneapolis, Minnesota, United States
Emmanuel Antonarakis
Recruiting
University of Nebraska Medical Center
Omaha, Nebraska, United States
Benjamin Teply, MD
Recruiting
University of Washington/fred Hutchinson Cancer Center
Seattle, Washington, United States
Michael Schweizer, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Enzalutamide →Testosterone →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 19 Aug 2020
Primary completion: 31 Jul 2027
Completion: 31 Jul 2028
Last update posted: 17 Jul 2026
Registered enrollment: 150
Registry id: NCT04363164

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.